{'fraction_non_alphanumeric': 0.014388489208633094, 'fraction_numerical': 0.0041109969167523125, 'mean_word_length': 5.581081081081081, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Synchronous metastasis from lobular carcinoma and primary carcinoma of the endometrium in a patient after tamoxifen therapy.

Patients treated with tamoxifen often experience vaginal bleeding, generally because of benign endometrial lesions or, less often, because of endometrial carcinoma. A rare cause of vaginal bleeding in these patients is breast carcinoma metastasis in an endometrial polyp. We describe a 67-yr-old patient with metastasis of lobular breast carcinoma in an endometrial polyp and papillary serous endometrial carcinoma, both diagnosed simultaneously in a uterine curettage. The coexistence of the 2 cancers was confirmed by pathologic study of the hysterectomy specimen. To our knowledge, this is the first reported case of the synchronous presence of the 2 neoplastic diseases. Endometrial biopsies performed for endometrial disorders in patients who have breast cancer and have received tamoxifen should be studied carefully to avoid underdiagnosis.